LOGIN
.jpg)
Subcutaneous Abaloparatide in Men with Osteoporosis
February 2023
Subcutaneous Abaloparatide in Men with Osteoporosis
Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
J Bone Miner Res. 2022 Dec;37(12): 2435-2442.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Two hundred and twenty-eight men with osteoporosis were randomized to receive 12 months of daily subcutaneous abaloparatide (n=149) or placebo (n=79). The primary outcome of interest was the change from baseline in lumbar spine bone mineral density (BMD). Secondary outcomes of interest include BMD of the femoral neck and hip and the incidence of new clinical fractures; safety outcomes were also as...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.